College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
College of Pharmacy, Freie Universität Berlin, Kelchstr. 31, 12169 Berlin, Germany.
Eur J Pharm Biopharm. 2024 Nov;204:114515. doi: 10.1016/j.ejpb.2024.114515. Epub 2024 Sep 24.
The removal of organic solvents during the preparation of biodegradable poly(D,L-lactide-co-glycolide) (PLGA) microparticles by an O/W- solvent extraction/evaporation process was investigated and controlled by diafiltration. Emulsification and steady replacement of the aqueous phase were performed in parallel in a single-vessel setup. During the process, the solidification of the dispersed phase (drug:PLGA:solvent droplets) into microparticles was monitored with video-microscopy and focused beam reflectance measurement (FBRM) and the residual solvent content was analyzed with headspace gas chromatography (organic solvent) and coulometric Karl-Fischer titration (water). Microparticles containing dexamethasone or risperidone were characterized with regard to particle size, morphology, encapsulation efficiency and in-vitro release. Diafiltration-accelerated solvent extraction shortened the process time by accelerating solidification of dispersed phase but reduced the residual dichloromethane content only in combination with increased temperature. Increasing the diafiltration rate increased particle size, porosity, and the encapsulation efficiency of risperidone. The latter effect was particularly evident with increasing lipophilicity of PLGA. A slower and more uniform solidification of end-capped and increased lactide content PLGA grade was identified as the reason for an increased drug leaching. Accelerated solvent extraction by diafiltration did not affect the in-vitro release of risperidone from different PLGA grades. The initial burst release of dexamethasone was increased by diafiltration when encapsulated in concentrations above the percolation threshold. Both porosity and burst release could be reduced by increasing the process temperature during diafiltration. Residual water content was established as an indicator for porosity and correlated with the burst release of dexamethasone.
在通过 O/W-溶剂萃取/蒸发过程制备可生物降解的聚(D,L-丙交酯-共-乙交酯)(PLGA)微球时,研究并通过渗滤控制了有机溶剂的去除。在单容器装置中,同时进行乳化和水相的稳定替换。在该过程中,通过视频显微镜和聚焦光束反射测量(FBRM)监测分散相(药物:PLGA:溶剂液滴)固化为微球的情况,并通过顶空气相色谱(有机溶剂)和库仑卡尔费休滴定(水)分析残留溶剂含量。用载有地塞米松或利培酮的微球进行特征描述,包括粒径、形态、包封效率和体外释放。渗滤加速溶剂萃取通过加速分散相的固化缩短了工艺时间,但仅在增加温度的情况下才能降低残留二氯甲烷含量。增加渗滤速率会增加粒径、孔隙率和利培酮的包封效率。当 PLGA 的亲脂性增加时,后者的效果更为明显。端封和增加丙交酯含量的 PLGA 等级的更缓慢和更均匀的固化被确定为药物浸出增加的原因。渗滤加速溶剂萃取不会影响不同 PLGA 等级利培酮的体外释放。当包封在超过渗透阈值的浓度时,渗滤会增加地塞米松的初始突释释放。通过增加渗滤过程中的温度可以降低孔隙率和突释释放。残余水分含量被确定为孔隙率的指标,并与地塞米松的突释释放相关。